Moderate to Severe Acute Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Moderate to Severe Acute Pain Market Outlook
Thelansis’s “Moderate to Severe Acute
Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Moderate to Severe Acute Pain
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Moderate to Severe Acute Pain Overview
Moderate
to severe acute pain is characterized by a sudden or urgent onset and is
typically associated with identifiable, treatable causes such as injury,
trauma, surgery, or other medical interventions. Opioids are highly effective
in managing acute nociceptive pain due to their potent analgesic properties.
However, their use is accompanied by significant risks, including serious
adverse effects and a high potential for abuse, addiction, and misuse. Despite
these risks, opioid analgesics remain indispensable in the treatment of
moderate to severe acute pain when non-pharmacological methods and non-opioid
analgesics fail to provide adequate relief. Recent data indicate that the
prevalence of opioid prescriptions for acute pain management remains substantial,
with a continued emphasis on balancing effective pain control and minimizing
the risk of opioid-related complications.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations
for target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment